Kornimate/medical-research-clean huggingface dataset:
study to develop a tool to estimate the kidney function in databases without laboratory data

Conditions: Renal Function

Summary: scientific analyses are frequently performed on e.g. health insurance databases to study the usage and effectiveness of drugs in real life. kidney function is known to have an influence on a patients disease development and/or drug levels in blood. however, often direct measures for kidney function are not available in databases. this study plans to develop tools to classify the renal function of patients, which helps scientists to identify patient cohorts (groups of patients sharing same characteristics) for scientific analyses.

renal impairment is a common comorbidity in patients with diverse main underlying diseases and a pathology accompanying increasing age. renal function might be an important modifier of treatment effects. population-based administrative claims databases are increasingly used in large-scale comparative outcomes studies of drug treatments. however, claims databases often lack information on laboratory tests results limiting their usefulness in real-world evidence(rwe) research of patients with renal impairment. there is a need to develop methods for identification of patients with renal dysfunction from healthcare administrative claims-based proxies. the main objective of this study is the development of algorithms/models to predict egfr values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (atrial fibrillation, coronary artery disease, type 2 diabetes mellitus patients sub-populations). to achieve this, modern data-driven machine learning techniques will be applied to discover relationships between renal status, measured by egfr, and longitudinal patient-level data. evaluation of models' performance (out of sample validation, benchmark test, performance differences between egfr value prediction algorithms and classification models tailored for the pre-defined egfr classes) will be done as well.

Eligibility criteria:
to be included in the egfr-population, patients have to have at least one recorded egfr value in the optum cdm database between january 1, 2007 and december 31, 2016, be adults (\>18 years of age at the time of egfr test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since egfr test date.

Keywords: renal function, egrf, atrial fibrillation, coronary artery disease, type 2 diabetes mellitus, machine learning, prognostic modeling
using technology to reduce youth substance use

Conditions: Drug Use

Summary: the research project will focus on conducting a trial of whether a tailored sms text-messaging intervention is efficacious in improving justice-involved youths' substance use or dual diagnosis treatment attendance and engagement.

the study will demonstrate how delivery of motivational/coaching messages to justice-involved youth and their caregivers will lead to greater youth substance use treatment attendance and engagement. the study will start with identifying the feasibility and acceptability of the sms text-messaging intervention with community-supervised justice-involved youth. then, the study will determine whether the tailored dyadic (youth and caregiver) sms text-messaging intervention improves justice-involved youth substance use or dual diagnosis treatment attendance and engagement relative to standard of care (not receiving motivational/coaching messages). finally, the study will characterize patterns of key justice and behavioral health system-level factors that promote or hinder eventual adoption and sustainability of mhealth technology as a tool to improve treatment attendance for justice-involved youth.

Eligibility criteria:
inclusion criteria: * english-speaking youth with willing adult caregiver * ages 13-18 * justice-involved while living in the community * own a mobile phone or tablet * are willing to send and receive text messages * are referred to community-based substance use and/or mental health treatment exclusion criteria: -

Keywords: adolescent juvenile justice text messaging substance use mhealth
vestibular rehabilitation with intratympanic drug therapy in meniere's disease

Conditions: Vestibular Disorder Preservation

Summary: intractable symptoms of meniere's disease will be treated with intratympanic steroids. at the same time intratympanic dexamethasone will be used to rescue hearing

for alleviation of intractable symptoms of meniere's disease will be treated with intratympanic steroids. measured with pre and post therapy vestibular severity index. at the same time intratympanic dexamethasone will be used to rescue hearing measured with speech reception threshold and speech discrimination threshold

Eligibility criteria:
inclusion criteria: * all patients of unilateral meniere's disease with severe vestibular symptoms exclusion criteria: * bilateral disease, operated cases

Keywords: dexamethasone, gentamicin
lactose-free milk in infants with acute diarrhea in a developing country

Conditions: Acute Gastroenteritis

Summary: the purpose of this study is to determine whether lactose-free milk will shorten the diarrhea duration and decrease its severity in formula-fed infants presenting to the emergency department (ed) or pediatric clinics with acute diarrhea.

acute gastroenteritis is a major cause of pediatric morbidity and mortality accounting for 15 % of all childhood death worldwide, and is a major public health burden, especially in developing countries. a recent cochrane review of 33 randomized or quasi-randomized trials reported a modest reduction in the duration of diarrhea in children younger than 5 years who were on reduced or lactose-free diet. those trials however were conducted on inpatients in high or middle-income countries. none were from developing countries where diarrheal diseases are severer and result in higher morbidities and mortalities. this study aims at investigating the effect of lactose-free milk on the duration and severity of diarrhea in infants from a developing country, who present with acute gastroenteritis to the emergency department (ed) or pediatric clinics. the findings from this study will help provide evidence-based dietary recommendations for infants with acute diarrhea in developing countries who are treated in the ambulatory setting.

Eligibility criteria:
inclusion criteria: * infants on artificial milk formula * presenting to the ed or pediatric clinics of the american university of beirut medical center * chief complaint: acute gastroenteritis (three or more loose or liquid stools in 24 hours, for at least 24 hours, and not exceeding 2 weeks from presentation, with or without fever, vomiting, mucus or blood per stools). exclusion criteria: * exclusively or partially breast-fed infants * severe dehydration requiring hospitalization

Keywords: diarrhea developing world lactose-free diet clinical trial
patterned multichannel vibrotactile stimulation for the longitudinal treatment of moderate stage parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (cr), for the alleviation of motor symptoms in patients with parkinson's disease (pd). pd patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. treatment for pd is either pharmacological (first line) or invasive deep brain stimulation. the non-invasive, vibrotactile stimulation approach uses a novel stimulation pattern to disrupt the pathophysiological mechanism that is responsible for pd symptoms and thus restore motor function.

up to thirty adults with bilateral, moderate stage idiopathic pd will be enrolled in this longitudinal study. participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals. this longitudinal protocol will be open-ended to enable continued treatment to those interested / motivated. study treatment will consist of daily, four-hour vibrotactile coordinated reset (vcr) stimulation sessions on a continual basis. all daily vcr stimulation sessions will occur at the participant's home (on-medication) and can be broken up into two, two-hour blocks (with no more than 12 hours between stimulation blocks) to be less cumbersome and better integrate into the participant's daily life. daily home-based treatment will be unsupervised, though timely support is guaranteed by synergic medical technologies (smt) support staff when needed (e.g., when usability or it issues arise). daily stimulation / device usage will be automatically logged by the device and continuously monitored by smt staff, meanwhile participants will keep a med diary so we can monitor their med usage (and how it relates to extended exposure) over time. participants will be able to transition to an as-needed basis with treatment after four months and once they are familiar with the treatment and their body's response to it, to better alleviate pd symptoms.

Eligibility criteria:
inclusion criteria: * between the ages 45 and 90 * diagnosis of bilateral, moderate stage idiopathic pd * qualify for eeg procedures exclusion criteria: * on dopamine agonist medications and exhibiting compulsive behaviors

Keywords: vibrotactile
melatonin for pediatric emergence agitation

Conditions: Emergence Agitation

Summary: efficacy of melatonin premedication on emergence agitation in children undergoing herniorrhaphy surgeries

before administration of the oral premedication, each patient's baseline heart rate, mean systemic arterial pressure, pulse oximetry, and sedation score (yale preoperative score) will be recorded all the anesthetic and surgical techniques will be standardized. on arrival at the operating room, continuous electrocardiogram, non-invasive blood pressure and pulse oximetry monitors will be applied. baseline readings of all the parameters will be recorded. sevoflurane 3-8 mac will be used for induction of anaesthesia. while intravenous line is inserted, atropine 0.01 mg/kg, atracurium 0.0.05 mg/kg is given. anaesthesia maintainance done by 1.5-2 mac sevoflurane. at the end of operation discontinuation of inhalational anesthesia will be done and muscle relaxant will be reversed by neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. then children were transferred to recovery till complete recovery parameters assessed are induction time (it) time from the start of sevoflurane inhalation to the start of endtracheal tube insertion, duration of anesthesia (da) time from the start of sevoflurane inhalation to discontinuation of sevoflurane inhalation, time up to spontaneous eye opening (time from removal of endotracheal tube till spontaneous eye opening), duration of stay in recovery and any side effects

Eligibility criteria:
inclusion criteria: * asa i * scheduled for unilateral inguinal herniorrhaphy * parents conscent exclusion criteria: * allergy to this study drug * patients with a history of cardiovascular, psychiatric, neurological, endocrine, chest disease, and/or severe renal or hepatic dysfunction

Keywords: melatonin emergence agitation
impact of physical activity on patients with chronic kidney disease not receiving dialysis followed in the tircel network. an exposed / unexposed study (physalys)

Conditions: Renal Insufficiency, Chronic

Summary: physalys is an observational multicenter study. it's an analytical study comparing 2 groups: patients exposed to physical activity and unexposed. the main objective of the study is to compare the evolution of glomerular filtration rate at inclusion and 12 months later between patients practicing physical activity and patients not practicing. if necessary, the renal disease-related complications, which are not influenced by physical activity: (type of kidney disease, age and tobacco), would be taken into account. tircel patients with chronic kidney disease (ckd) at stages 3, 4 or 5 can be included in the study. their serum creatinine data, 12 months prior to inclusion, is collected retrospectively. patients are followed in the trial during 12 months. to evaluate physical activity, patients respond to global physical activity questionnaire 2 (gpaq2) at inclusion and 12 months later. during this 12 months period, the same biological data are collected prospectively.


Eligibility criteria:
inclusion criteria: * members of tircel (traitement de l'insuffisance chronique en rhône-alpes) network for over a year and having at least two measurements of glomerular filtration rate with an interval of 9 to 12 months between the first and the last measurement * patients in stages 3, 4 or 5 of ckd * no dialysis ckd patients * non transplanted ckd patients * patients seeing nephrologist * patients agreeing to be contacted for a phone call half an hour * adults patients (\> 18 years) * patients not living in institution * patients being able to answer a questionnaire exclusion criteria: * patients followed in the tircel (traitement de l'insuffisance chronique en rhône-alpes) network for less than one year or having less than 2 measurements of glomerular filtration rate with an interval of least 9 months or over 12 months between the first and the last measurement * patients in stages 1 or 2 of ckd * ckd patients receiving dialysis * transplanted ckd patients * patients not seeing nephrologist * patients refusing to be contacted for a phone call half an hour * patients \< 18 years * patients living in institution * patients unable to answer a questionnaire

Keywords: physical activity chronic kidney disease nephrology stage 3 stage 4 stage 5
genetic biomarker discovery for metastatic prostate cancer

Conditions: Prostate Cancer

Summary: biomarkers from circulating cell-free tumor dna in peripheral blood will identify patients with metastatic prostate cancer diagnosed with c11 choline pet/ct who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. tissue and blood will be collected before treatment. if patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.


Eligibility criteria:
inclusion criteria: * men age 18 years old and older. * histologically proven diagnosis of prostate cancer. * radiographic evidence of non-regional lymph node involvement, pelvic lymph node recurrence, and/or bone metastases. * requiring a clinically directed biopsy or resection of tumor at mayo clinic rochester. * receiving local therapy for metastatic disease with radiation, ablative therapies, and/or surgery at mayo clinic rochester. * willingness to provide blood sample prior to receipt of treatment, as well as after neoadjuvant androgen deprivation therapy and at 3 months and 6 months after radiation, ablation, or surgery. * absence of a second active malignancy. * an understanding of the protocol and its requirements, risks, and discomforts. * the ability and willingness to sign an informed consent. exclusion criteria: * inability on the part of the patient to understand the informed consent or be compliant with the protocol. * history of a serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).
a study to evaluate the safety and efficacy of aprepitant (mk0869) for chemotherapy-induced nausea and vomiting in pediatric patients

Conditions: Chemotherapy-Induced Nausea and Vomiting

Summary: aprepitant was approved in 2003. the drug works to lessen the amount of nausea and vomiting that cancer patients experience after treatment. aprepitant has been well-studied in adults, but not in children. data from adult studies has shown aprepitant to be safe. it has also been shown to be effective in lessening the amount of nausea and vomiting that adult patients experience. because aprepitant has been shown to be safe and effective, the investigators have been using it in pediatric patients at this hospital as standard of care. the investigators will be surveying patients already receiving aprepitant for prevention of chemotherapy-induced nausea and vomiting to determine the amount of nausea and vomiting they experience. the investigators will also be surveying these patients to determine what their appetite is like and if they experience any disruptions in activities of daily living. the investigators are also going to be assessing any side effects these patients experience from receiving aprepitant.

this will be a prospective, observational study conducted at wvu children´s hospital. the study will be conducted over a one-year period until data from 20-40 patient encounters is obtained. there will be no randomization and no control group. information will be collected from all patients who meet the study´s inclusion criteria. patients will be given a survey to complete at baseline, on all days of chemotherapy, and for five days after the conclusion of chemotherapy using the barf scale and a 4-point likert scale. the information collected from the survey will include the incidence and severity of nausea and emesis, evaluation of appetite, activities of daily living, and rescue medications used for acute cinv. the specific chemotherapy regimen that each patient receives will be recorded. any data identifying the patient will be de-identified after all pertinent data is collected. descriptive statistics will be used to analyze data.

Eligibility criteria:
inclusion criteria: 1. patient is between the ages of 1-17 years 2. patient has a confirmed malignancy 3. patient is receiving highly or moderately emetogenic chemotherapy 4. receiving aprepitant as part of an anti-emetic regimen 5. patient's legally-authorized representative understands and voluntarily signs the written informed consent prior to any study-specific procedures. a copy of the signed informed consent form will be retained by the treating institution. 6. patient ≥7 years of age understands and voluntarily signs the written informed assent form prior to any study specific procedures. a copy of the signed informed assent form will be retained by the treating institution. exclusion criteria: 1. pregnant or breast feeding 2. concomitant use of pimozide, terfenadine, astemizole, or cisapride 3. child-pugh score \> 9 4. receiving iv fosaprepitant

Keywords: aprepitant pediatrics chemotherapy-induced nausea/vomiting survey
testicular injection of autologous stem cells for treatment of patients with azoospermia

Conditions: Azoospermia

Summary: azoospermia is defined as the complete lack of sperm in the ejaculate. in humans, azoospermia affects about 1% of the male population and may be seen in up to 20% of male infertility situations. in testicular azoospermia the testes are abnormal, atrophic, or absent, and sperm production severely disturbed to absent. fsh levels tend to be elevated (hypergonadotropic) as the feedback loop is interrupted. the condition is seen in 49-93% of men with azoospermia. the purpose of this study is to assess the ability of bone marrow derived stem cells to differentiate into germ cells and their role in treatment of testicular azoospermia

this study is an open-label investigation of the efficacy of injection autologous adult bone marrow derived stem cells into the somniferous tubules or interstitial spaces of male testis with azospermia. sixty men with azoospermia will be recruited in this study after a written informed consent. the diagnosis of azoospermia will be established on the basis of two semen analysis evaluations done at separate occasions; this will be followed by detailed history taking, physical examination and investigations. history taking will include general health, sexual health, past fertility, libido, sexual activity and previous exposure to surgery, drugs, mumps infection and irradiation. physical examination includes genital and local examination for detection of signs of klinefelter syndrome, testicular atrophy, absence of vas. investigations include serum fsh, lh, karyotyping and testosterone levels, and may include testicular biopsy or transrectal ultrasound if indicated (low levels of lh and fsh with low or normal testosterone levels are indicative of pretesticular problems, while high levels of gonadotropins indicate testicular problems. however, often this distinction is not clear and the differentiation between obstructive versus non-obstructive azoospermia may require a testicular biopsy). subjects will be enrolled based on specific inclusion/exclusion criteria and evaluated at regular post transplant intervals. human adult bone marrow derived stem cells will be transplanted by an andrological surgeon through a standard surgical approach. subjects will be monitored frequently for a total of one year after adult bone marrow stem cells cell injection. for safety of participants, bone marrow stem cells will be injected in one testis only and the other testis will be spared.

Eligibility criteria:
inclusion criteria: * patients with non-obstructive azoospermia * patients between 25 - 60 years old. exclusion criteria: * patients with obstructive azoospermia * men with previous surgery in testis * men with infectious genital diseases and anatomical abnormalities of the genital tract * those with major medical problems such as malignancy, hepatitis, etc. * chromosomal aberration (e.g. y microdeleion, trisomy....)
bone metastasis on the survival of gefitinib effective patients

Conditions: Overal Survival, Non-small Cell Lung Cancer

Summary: gefitinib is a selective small molecule epidermal growth factor receptors (egfr) tyrosine kinase inhibitors (egfr-tki), it's curative effect on non-small cell lung cancer (nsclc) has been confirmed by a number of prospective clinical trials. the researches aim to analysis whether bone metastasis could affect the survival of nsclc patients who were effective in gefitinib treatment over 6 months.

the epidermal growth factor receptors (egfrs) have inhibitory effects on cell apoptosis, cell growth, angiogenesis and metastasis of tumor cell. the advent of egfr-tki significantly improved the clinical efficacy and safety of non-small cell lung cancer (nsclc) treatment. compelling study also demonstrate gefitinib may be effective in the treatment of bone metastases. for nsclc patients who were effective in egfr-tki treatment, whether bone metastasis would shorten the survival time of the patients or reduce the quality of life of patients is worth studying. the researches aim to analysis whether bone metastasis could affect the survival of nsclc patients who were effective in gefitinib treatment over 6 months.

Eligibility criteria:
inclusion criteria: 1. histological and (or) cytological diagnosed nsclc patients. 2. patient was effective in gefitinib treatment more than 6 months. 3. whether patient received chemotherapy and other treatment is not restricted. 4. whether patient was detected for egfr gene mutation was not restricted. exclusion criteria: 1. patient with small cell lung cancer. 2. patient without cytology or histopathology diagnosis results. 3. patient with bone metastases cannot rule out other reasons such as inflammation or trauma. 4. patient with poor treatment compliance. 5. patient with incomplete data.